TNF and rheumatoid arthritis: This, in turn, influences tumor migration and indirectly augments the release of tumor growth-promoting factors (255).The FDA has approved a variety of anti-TNF-α biologics, such as infliximab and etanercept, for the treatment of moderate to severe RA, and the etanercept has been extended to juvenile RA, and the indication for etanercept has been extended to the treatment of juvenile RA (256).